Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Automated and Closed Cell Therapy Processing Systems Market Set for Expansion as Scalable Workflows Drive Growth, 2026-2033

globenewswire.com

Global Automated and Closed Cell Therapy Processing Systems Market Set for Expansion as Scalable Workflows Drive Growth, 2026-2033 Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Global Automated and Closed Cell Therapy Processing Systems Market Size, Share & Industry Analysis Report by Type, Scale, Workflow, Regional Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global automated and closed cell therapy processing systems market is projected to reach USD 7.0 billion by 2033, expanding at a compound annual growth rate (CAGR) of 20.2% from 2026 to 2033. Market growth is being driven by accelerating investment in regenerative medicine, CAR-T cell therapies, stem cell therapies, personalized medicine, and advanced therapy medicinal products.

Healthcare organizations, biotechnology and pharmaceutical companies, contract development and manufacturing organizations, hospitals, and research institutions are increasingly adopting automated and closed cell therapy processing systems to improve manufacturing efficiency, scalability, safety, consistency, and regulatory compliance. The transition from manual, labor-intensive, and open processing methods toward integrated closed-system platforms is helping manufacturers reduce contamination risk, limit operator dependency, enhance reproducibility, and support progression from clinical development to commercial production.

Market Insights

Market Growth Drivers and Opportunities

Growth in the automated cell therapy manufacturing market is supported by expanding cell and gene therapy pipelines, increasing commercialization of CAR-T treatments, and rising demand for autologous and allogeneic therapies. Manufacturers are prioritizing closed processing, single-use technologies, process analytics, modular platforms, and digitally controlled production environments to improve throughput and maintain product quality.

Artificial intelligence and data-driven process analytics represent significant opportunities for predictive manufacturing optimization, real-time monitoring, and improved quality control. Modular automation platforms could also enable decentralized and point-of-care manufacturing by supporting flexible deployment across early-stage research, clinical production, and regional treatment centers.

Market adoption may be constrained by high capital and operating costs, complex validation requirements, stringent quality standards, and limitations in platform interoperability. Integrating multiple processing stages into a unified closed workflow also remains technically challenging, particularly when manufacturers handle diverse cell types, treatment formats, and production volumes.

Type, Scale, and Workflow Outlook

Non-stem cell therapy is expected to remain the leading type segment through 2033, supported by the development of CAR-T, T-cell receptor, natural killer cell, and other engineered cell therapies. These products require tightly controlled collection, isolation, activation, expansion, genetic modification, washing, concentration, and formulation processes. Stem cell therapy is also gaining momentum across regenerative medicine, tissue engineering, autoimmune disease research, neurological applications, orthopedic treatments, cardiovascular repair, and wound healing.

Pre-commercial and R&D-scale systems will continue to represent a substantial share of demand as academic institutions, biotechnology startups, and early-stage developers invest in flexible platforms for process development, clinical trial materials, protocol optimization, and small-batch production. Commercial-scale adoption is expected to accelerate as late-stage therapies advance toward approval and manufacturers require higher throughput, traceability, reproducibility, and GMP-compliant production.

Separation remains the leading workflow because cell therapy manufacturing requires reliable isolation of target cells from complex biological samples. Expansion systems are essential for producing clinically relevant cell volumes, while apheresis supports autologous and allogeneic collection. Automated fill-finish platforms improve aseptic processing and dosing consistency, and cryopreservation systems support storage, transportation, and treatment scheduling.

Regional Market Outlook

North America is expected to retain its market leadership through 2033, supported by substantial biopharmaceutical investment, advanced manufacturing infrastructure, high clinical trial activity, and continued commercialization of cell and gene therapies. Europe is projected to grow at a CAGR of 19.9%, benefiting from regenerative medicine research, established advanced therapy regulations, and expanding biomanufacturing capacity.

Asia Pacific is forecast to register a CAGR of 21.3% as China, Japan, India, South Korea, Singapore, and Australia increase biotechnology investment, clinical research, and healthcare infrastructure. LAMEA remains an emerging market but is expected to grow rapidly as investment in advanced therapeutics and automated cell processing expands across Latin America, the Middle East, and Africa.

Competitive Landscape

The automated and closed cell therapy processing systems market is moderately consolidated. Competition centers on end-to-end automation, single-use processing, digital integration, modularity, process analytics, regulatory compliance, and commercial scalability. Thermo Fisher Scientific Inc. holds a leading position through its broad cell processing, bioprocessing, analytical, and manufacturing portfolio. Cytiva, Sartorius AG, Miltenyi Biotec, and Lonza Group also maintain strong positions in automated processing and scalable cell therapy manufacturing.

Other notable participants include Fresenius Kabi, Terumo BCT, Bio-Techne, Cellares, and Merck KGaA. Recent industry activity includes the expansion of Cytiva's Sefia platform, Cellares' development of automated Smart Factories, Cytiva's collaboration with NecstGen, the partnership between MiLaboratories and Miltenyi Biotec, and the extension of Sartorius and Siemens' automation collaboration.

Companies Profiled

Market Segmentation

For more information about this report visit https://www.researchandmarkets.com/r/1c82fg

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.